ISRG — Q3 2026 Financial Report Analysis

A record quarter for the business, a $450 million legal bill for the shareholders

Intuitive Surgical makes the da Vinci surgical robots and the Ion lung-biopsy robot. Hospitals buy or lease the machines, then pay for single-use instruments and service contracts every time a surgeon operates with one. Most of the money comes from that second stream, which is why procedure volume matters more than how many robots get sold in any one quarter.

In the quarter to September 30, 2026, both streams sped up. Revenue rose 22% to $3.05 billion, faster than the 19% of the June quarter. Intuitive placed 546 da Vinci systems, up from 427 a year earlier, and da Vinci procedures grew about 14%. Underneath, the business got more profitable.

The reported profit fell anyway. Intuitive took a $450 million charge to settle a long-running antitrust class action (a lawsuit by customers alleging anti-competitive practices), and that one item turned GAAP operating income (profit from running the business, before interest and tax, under standard accounting rules) from what would have been about $1.05 billion into $593 million. GAAP diluted earnings per share fell 24% to $1.49. Excluding the settlement and the company's other usual adjustments, EPS rose 25% to $3.00.

This report is written from the earnings release Intuitive filed on October 20, 2026 (Form 8-K, Exhibit 99.1). The full Q3 10-Q is not filed yet, so the U.S. vs. international split, China commentary, average selling prices, trade-ins and the cash flow statement are not available to us yet.

The quarter in numbers

All figures from the Q3 2026 earnings release. Percentage changes are computed from the release's figures. "Non-GAAP" is the company's own adjusted measure; what it removes is covered below.

Where the growth came from

Instruments and accessories (59% of revenue) grew 18%. The release attributes this "primarily" to about 14% growth in da Vinci procedures and about 31% growth in Ion procedures. Instrument revenue growing a few points faster than da Vinci procedures matches what the Q2 10-Q described: newer da Vinci 5 and single-port systems use more instrument revenue per operation, and Ion is growing much faster from a smaller base. Chief executive Dave Rosa said customers performed "on average, over 10,000 procedures per day" during the quarter.

Systems revenue grew 30%, the fastest of the three lines. The release credits more da Vinci placements and a larger base of leased systems. Of the 546 systems placed, 291 (53%) went out on operating leases (rental-style contracts where revenue comes in over time instead of upfront), and 160 of those were usage-based, meaning the hospital pays per procedure. A year ago it was 231 leases out of 427 (54%), 115 of them usage-based. So the lease share held steady while the number of systems placed rose sharply, and the newest model made up 58% of placements (315 da Vinci 5 out of 546).

Services revenue grew 22%, tracking the 12% larger installed base plus the shift to newer systems.

Ion placements grew less than procedures. Intuitive placed 56 Ion systems against 50 a year ago (+12%), while Ion procedures grew 31% and the Ion installed base grew 21% to 1,152. More of the Ion growth is coming from existing systems being used more, not from new installations.

What the headline numbers hide

The settlement is a real cash cost, but a one-time one. In October 2026, after mediation, Intuitive agreed to settle the In re: da Vinci Surgical Robot Antitrust Litigation class action for a one-time $450 million payment plus "mutually agreed injunctive relief" (changes to business practices the release does not describe), without admitting liability. The full $450 million was booked in Q3 selling, general and administrative expense (SG&A). Total litigation charges in the quarter were $454.9 million. The settlement still needs preliminary and final court approval. Unlike most adjustments, this one will be paid in cash, so excluding it from "underlying" profit is fair for judging the quarter's operations but not for judging what shareholders got.

Excluding litigation, GAAP margins widened by about four points. Adding back litigation charges in both years, GAAP operating income would have been $1,047.5 million (34.4% of revenue) against $767.8 million (30.6%) a year earlier. SG&A excluding litigation grew 11.2% ($628.5 million against $565.2 million), about half the rate of revenue.

Tariff refunds came back, contrary to our Q2 expectation. Cost of revenue included $27.8 million of refunds on tariffs paid in earlier periods under the International Emergency Economic Powers Act (IEEPA), which the U.S. Supreme Court struck down in February 2026. That follows $35.9 million in Q2, for $63.7 million so far this year. In Q3 the refunds added $0.06 to both GAAP and non-GAAP EPS; the company does not remove them from its adjusted figures. Without them, GAAP gross margin would have been about 67.5% rather than 68.4%, still up about one point from 66.4% a year ago.

The non-GAAP gap is wide and mostly recurring. Non-GAAP EPS ($3.00) is double GAAP EPS ($1.49). Of the $1.51 difference, $1.29 before tax is litigation and $0.60 is share-based compensation (pay to employees in stock), offset by $0.41 of tax adjustments. Stock-based pay ($212.6 million this quarter) recurs every quarter, and the release itself calls it "a significant recurring expense." Treat non-GAAP figures as flattering by about $0.60 a share every quarter, not just this one.

Operating costs are growing faster than full-year guidance. Using the release's reconciliation, non-GAAP operating expenses were about $860 million in Q3, up 18% from about $728 million a year earlier. For the first nine months they were up about 14% ($2,468 million against $2,168 million). Management's full-year guidance is for 11% to 13% non-GAAP operating expense growth. These are our calculations, not company figures. Reaching that range would need fourth-quarter expense growth well below the year-to-date pace. The main driver is research and development, up 24% to $408.3 million. Some of the cost growth also comes from the distributor businesses in Italy, Spain and Portugal that Intuitive bought in March and now runs itself.

Part of the EPS growth came from buybacks, not operations. Diluted shares fell 2.8% to 351.6 million. Non-GAAP net income grew 21.6% while non-GAAP EPS grew 25.0%, so about three points of the per-share growth came from the smaller share count. Most of the 7.8 million shares bought back in Q3 are not yet fully reflected in the average share count, so the Q4 count should fall further. The cost: interest and other income fell 21% to $75.8 million as cash was spent.

The tax rate went up, not down. The GAAP effective tax rate (tax as a share of pre-tax profit) was about 21.5% against 17.1% a year ago. The year-ago quarter had a $22.5 million one-time tax benefit and larger excess tax benefits from employee stock awards ($24.2 million against $12.6 million). This quarter's EPS did not get a lift from tax.

Receivables and inventory look under control, but cash flow is still unknown. Accounts receivable rose 12.7% since December to $1,721 million, and inventory rose 15.7% to $2,128 million. Both grew less than nine-month revenue (+21%). The release has no cash flow statement, so we can't check how much of net income turned into operating cash this quarter. That waits for the 10-Q. Accounts payable and other liabilities rose $643 million since year-end. The release does not say where the unpaid settlement is recorded.

Takeaway: Ignore the 24% GAAP EPS drop. A one-time $450 million settlement caused it, and outside that charge the quarter was the strongest of the year: revenue growth sped up to 22%, placements rose 28%, and operating margin excluding litigation widened about four points. The figures to watch are elsewhere. Da Vinci procedure growth slowed again, to about 14% from 15% in Q2. Expenses are running ahead of management's own full-year cost guidance. And with the $2.94 billion of buybacks, much of this year's EPS growth is now coming from a shrinking share count.

Year to date

Net income grew far more slowly than operating income for two reasons. The first is the settlement. The second is a higher tax rate: about 18.4% against 11.8%, because excess tax benefits from employee stock awards halved to $103.2 million from $202.5 million. Those benefits rise and fall with Intuitive's own share price, and last year's were unusually large.

Did last time's read hold up?

Our Q2 2026 report expected "mid-to-high-teens revenue growth with margins roughly flat to modestly up on an underlying basis," and said the tariff refund "does not recur." It also said to watch slowing procedure growth and China's new national price caps on robotic surgery.

• Revenue: better than we expected. Revenue grew 22%, above the mid-to-high-teens range we suggested.
• Underlying margin: held, slightly better. Excluding litigation and tariff refunds, GAAP operating margin was about 33.4%, against about 32.4% in Q2 on the same basis and 30.6% a year ago.
• Tariff refund: we were wrong. Another $27.8 million of refunds arrived in Q3.
• Procedure growth: the slowdown continued. Da Vinci procedure growth eased to about 14% from 15%, and Ion to about 31% from 36%.
• China: still unknown. The release says nothing about China. That has to wait for the 10-Q.

What management expects, and our read

The release gives full-year 2026 guidance on three measures:

• Worldwide da Vinci procedure growth of about 14% to 15%, "closer to the midpoint." This is consistent with Q2's ~15% and Q3's ~14%, and implies a similar pace in Q4.
• Non-GAAP gross margin of 68.7% to 69.3%. This includes an estimated 0.9% of revenue hit from tariffs currently in effect, excluding refunds. Year to date it is 69.2%, at the top of that range, and the company warns that new tariffs beyond current ones could have a material effect.
• Non-GAAP operating expense growth of 11% to 13%. As noted above, the year-to-date run rate by our calculation is about 14%.

The release does not repeat earlier guidance ranges, so this filing alone can't tell us whether these were raised or lowered.

Our read: the core business looks healthy. The installed base passed 12,000 da Vinci systems, placements rose faster than the installed base, and da Vinci 5 is a majority of new placements. Each new system adds instrument and service revenue for years, so mid-teens procedure growth translating into high-teens to low-20s revenue growth looks sustainable for now. Three things could change that. First, procedure growth slipping below the guided range, which would extend the gradual slowdown seen through 2026. Second, cost growth not slowing in Q4 the way the opex guidance implies. Third, the court approval process for the settlement, together with the "injunctive relief" terms, which may limit how Intuitive does business with hospitals. The 10-Q should describe those terms, along with China, the U.S./international split and cash flow.